Literature DB >> 6324788

S1-nuclease mapping of the genomic Lepore-Boston DNA demonstrates that the entire large intervening sequence of the fusion gene is of beta-type.

Y Chebloune, D Poncet, G Verdier.   

Abstract

Several reports have suggested but not proven that the large intervening sequence of Lepore delta-beta fusion gene was of beta-type (3-5). A method able to detect rearrangements as small as 4 nucleotide pairs directly into genomic DNA (6) has been applied to the total DNA of a heterozygous Lepore-Boston patient in order to identify accurately the origin of the large intervening sequence of the delta-beta fusion-gene. Hybrid duplexes were formed between genomic Lepore DNA and single-stranded DNA used as probes, then submitted to S1-nuclease treatment. Our data demonstrate that the entire large intervening sequence of the Lepore fusion gene is of beta-type. Moreover, no large modification was detected in any delta- and beta parts of the delta-beta fusion gene.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6324788     DOI: 10.1016/0006-291x(84)91421-9

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Characterization of chromosomes with hybrid genes for Hb Lepore-Washington, Hb Lepore-Baltimore, Hb P-Nilotic, and Hb Kenya.

Authors:  K D Lanclos; J Patterson; G D Efremov; S C Wong; A Villegas; P J Ojwang; J B Wilson; F Kutlar; T H Huisman
Journal:  Hum Genet       Date:  1987-09       Impact factor: 4.132

2.  Homology requirements for unequal crossing over in humans.

Authors:  A B Metzenberg; G Wurzer; T H Huisman; O Smithies
Journal:  Genetics       Date:  1991-05       Impact factor: 4.562

3.  Structural analysis of the 5' flanking region of the beta-globin gene in African sickle cell anemia patients: further evidence for three origins of the sickle cell mutation in Africa.

Authors:  Y Chebloune; J Pagnier; G Trabuchet; C Faure; G Verdier; D Labie; V Nigon
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.